BioNTech SE (BNTX) Current Ratio: 7.54
Is BioNTech SE’s current ratio high or low?
BioNTech SE's current ratio of 7.54 is 16% above its 5-year average of 6.49, near the high end of its 5-year range (2.75–9.43).
The current ratio for BioNTech SE (BNTX) is 7.54 as of Wednesday, June 10, 2026. It is above its 12-month average by 0.60% (7.50).
BNTX Current Ratio Chart
BNTX Average Current Ratio Chart
BNTX Current vs Average Current Ratio Chart
BNTX Current Ratio Metrics
CURRENT RATIO
7.54
CURRENT RATIO AVG TTM
7.50
CURRENT RATIO AVG 3Y
7.96
CURRENT RATIO AVG 5Y
6.49
CURRENT RATIO AVG 10Y
5.34
CURRENT RATIO AVG 15Y
5.34
CURRENT RATIO AVG 20Y
5.34
CURRENT VS TTM AVG
+0.60%
CURRENT VS 3Y AVG
-5.31%
CURRENT VS 5Y AVG
+16.21%
CURRENT VS 10Y AVG
+41.30%
CURRENT VS 15Y AVG
+41.30%
CURRENT VS 20Y AVG
+41.30%
BNTX Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | — | 7.54 | 7.50 | 7.96 | 6.49 |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 1.14 | 1.08 | 1.10 | 1.13 |
| Waters Corporation (WAT) | $23.83B | 1.73 | 1.92 | 2.08 | 2.07 |
| Moderna, Inc. (MRNA) | $18.40B | 3.29 | 3.48 | 3.28 | 2.72 |
| Hologic, Inc. (HOLX) | $16.97B | 3.75 | 3.72 | 3.76 | 3.20 |
| Veeva Systems Inc. (VEEV) | $26.73B | 4.89 | 4.70 | 4.39 | 4.08 |
| Biogen Inc. (BIIB) | $29.00B | 2.68 | 2.02 | 2.25 | 2.11 |
| DexCom, Inc. (DXCM) | $29.24B | 1.88 | 1.67 | 2.04 | 3.15 |
| IQVIA Holdings Inc. (IQV) | $30.60B | 0.75 | 0.79 | 0.83 | 0.90 |
| Align Technology, Inc. (ALGN) | $12.56B | 1.36 | 1.29 | 1.26 | 1.29 |
Liquidity Analysis
Current Ratio
7.54
Quick Ratio
7.49
BioNTech SE Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE Current Ratio FAQ
- What is the current ratio for BioNTech SE (BNTX)?
- The current ratio for BNTX stock is 7.54.
- Is BioNTech SE's current ratio high or low?
- BioNTech SE's current ratio of 7.54 is 16% above its 5-year average of 6.49, near the high end of its 5-year range (2.75–9.43).
- What is the TTM average current ratio for BioNTech SE (BNTX)?
- The TTM average current ratio for BNTX stock is 7.50.
- What is the 3Y average current ratio for BioNTech SE (BNTX)?
- The 3Y average current ratio for BNTX stock is 7.96.
- What is the 5Y average current ratio for BioNTech SE (BNTX)?
- The 5Y average current ratio for BNTX stock is 6.49.
- What is the 10Y average current ratio for BioNTech SE (BNTX)?
- The 10Y average current ratio for BNTX stock is 5.34.
- What is the 15Y average current ratio for BioNTech SE (BNTX)?
- The 15Y average current ratio for BNTX stock is 5.34.
- What is the 20Y average current ratio for BioNTech SE (BNTX)?
- The 20Y average current ratio for BNTX stock is 5.34.
BioNTech SE Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 7.54 |
| 2024-12-31 | 7.45 |
| 2023-12-31 | 9.43 |
| 2022-12-31 | 7.43 |
| 2021-12-31 | 4.33 |
| 2020-12-31 | 2.75 |
| 2019-12-31 | 4.05 |
| 2018-12-31 | 3.56 |
| 2017-12-31 | 1.20 |
| 2016-12-31 | 5.62 |
Related Metrics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin